Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

Fox, Kim, Ford, Ian, Steg, P. Gabriel, Tendera, Michal and Ferrari, Roberto and BEAUTIFUL Investigators (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, 372 (9641). pp. 807-816. ISSN 0140-6736

Full text not available from this repository.

Abstract

Ivabradine specifically inhibits the I(f) current in the sinoatrial node to lower heart rate, without affecting other aspects of cardiac function. We aimed to test whether lowering the heart rate with ivabradine reduces cardiovascular death and morbidity in patients with coronary artery disease and left-ventricular systolic dysfunction.

Item Type:	Article
Uncontrolled Keywords:	aged,benzazepines,coronary disease,double-blind method,female,follow-up studies,heart rate,hospital mortality,humans,kaplan-meier estimate,male,middle aged,ventricular dysfunction, left
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health
Depositing User:	Pure Connector
Date Deposited:	17 Mar 2015 11:14
Last Modified:	16 Apr 2024 13:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/52755
DOI:	10.1016/S0140-6736(08)61170-8

Actions (login required)

View Item